Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Published:2022-07-15 Issue:14 Volume:65 Page:9662-9677
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Eno Meredith S.¹^ORCID,Brubaker Jason D.¹,Campbell John E.¹,De Savi Chris¹,Guzi Timothy J.¹,Williams Brett D.¹,Wilson Douglas¹,Wilson Kevin¹^ORCID,Brooijmans Natasja¹,Kim Joseph¹,Özen Ayşegül¹,Perola Emanuele¹,Hsieh John¹,Brown Victoria¹,Fetalvero Kristina¹,Garner Andrew¹,Zhang Zhuo¹,Stevison Faith¹,Woessner Rich¹,Singh Jatinder¹,Timsit Yoav¹,Kinkema Caitlin¹,Medendorp Clare¹,Lee Christopher¹,Albayya Faris¹,Zalutskaya Alena¹,Schalm Stefanie¹,Dineen Thomas A.¹

Affiliation:

1. Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00704

Reference62 articles.

1. International Agency for Research on Cancer. Lung. GLOBOCAN World Fact Sheet, 2020, https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf (accessed Oct 4, 2021).

2. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

3. Overview of current systemic management of EGFR-mutant NSCLC

4. Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecule agents for triple negative breast cancer: Current status and future prospects;Translational Oncology;2024-03

2. Clinical application of liquid biopsy genomic profiling in NSCLC: Asian perspectives;The Journal of Liquid Biopsy;2024-03

3. Liquid biopsy for the management of NSCLC patients under osimertinib treatment;Critical Reviews in Clinical Laboratory Sciences;2024-02-02

4. Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?;Journal of Thoracic Oncology;2024-02

5. Identification of novel aminopyrimidine derivatives for the treatment of mutant NSCLC;European Journal of Medicinal Chemistry;2024-02